ArticleScientific reports2018
Advanced spectroscopy-based phenotyping offers a potential solution to the ash dieback epidemic.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Early-Stage Growth Restriction ofMicroorganisms · 2026Article
- Constitutive Metabolite Profiling of European and Asian Fraxinus with Varying Susceptibility to Ash Dieback.Journal of chemical ecology · 2026Article
- A recent ash dieback infection neither affects emerald ash borer performance nor triggers a substantial systemic phytochemical defense response in European ash.Journal of pest science · 2026Article
- Near-infrared spectroscopy as a high-throughput phenotyping method for fusiform rust resistance in loblolly pine.Plant phenomics (Washington, D.C.) · 2025Article
- Evolution of Thermal Plasticity inEcology and evolution · 2025Article
- Article
- Host-Pathogen Interactions in Leaf Petioles of Common Ash and Manchurian Ash Infected withMicroorganisms · 2022Article
- Transformation of European Ash (Plants (Basel, Switzerland) · 2021Article
- Diversity of secoiridoid glycosides in leaves of UK and Danish ash provide new insight for ash dieback management.Scientific reports · 2020Article
- Transcriptional responses in developing lesions of European common ash (Fraxinus excelsior) reveal genes responding to infection by Hymenoscyphus fraxineus.BMC plant biology · 2020Article
- The Relationship between Fungal Diversity and Invasibility of a Foliar Niche-The Case of Ash Dieback.Journal of fungi (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural and urban forests worldwide are increasingly threatened by global change resulting from human-mediated factors, including invasions by lethal exotic pathogens. Ash dieback (ADB), incited by the alien invasive fungus Hymenoscyphus fraxineus, has caused large-scale population decline of European ash (Fraxinus excelsior) across Europe, and is threatening to functionally extirpate this tree species. Genetically controlled host resistance is a key element to ensure European ash survival and to restore this keystone species where it has been decimated. We know that a low proportion of the natural population of European ash expresses heritable, quantitative resistance that is stable across environments. To exploit this resource for breeding and restoration efforts, tools that allow for effective and efficient, rapid identification and deployment of superior genotypes are now sorely needed. Here we show that Fourier-transform infrared (FT-IR) spectroscopy of phenolic extracts from uninfected bark tissue, coupled with a model based on soft independent modelling of class analogy (SIMCA), can robustly discriminate between ADB-resistant and susceptible European ash. The model was validated with populations of European ash grown across six European countries. Our work demonstrates that this approach can efficiently advance the effort to save such fundamental forest resource in Europe and elsewhere.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.